March 31, 2020

Post-Traumatic Stress Disorder Therapeutics Market Is Projected To Reach Worth US$ 10,679.5 Mn By 2026

According to the latest report published by Credence Research, Inc. “Post-Traumatic Stress Disorder Therapeutics Market – Growth, Future Prospects, and Competitive Analysis, 2018-2026,” the global market for post-traumatic stress disorder therapeutics is projected to reach US$ 10,679.5 million by 2026, increasing to CAGR by 4.5 percent from 2018 to 2026.

Market Insights                                                  

Post-traumatic stress disorder (PTSD) therapeutics market is projected to an extent by US$ 10,679.5 Mn by 2026 with a CAGR of 4.5% throughout the forecast period from 2018 to 2026. Antidepressants are the class of promising drugs that play a stellar role in the market. Global post-traumatic stress disorder therapeutics market from 2018 to 2026 has been prepared based on exhaustive analysis with insights from industry professionals. The detailed study incorporates the market landscape and its growth scenarios for the forecast period from 2018 to 2026. To estimate the market size, the report ruminates branded, generic and pipeline drugs.

Browse Full Report Originally Published by Credence Research at https://www.credenceresearch.com/report/post-traumatic-stress-disorder-therapeutics-market

As per the U.S. National Comorbidity Survey Replication, around 6.8% of individuals experience the ill effects of PTSD. As indicated by PTSD United, Inc. around 70% of individuals in the United States has encountered a few sorts of the shocking accident in any event once in their lives. This associate with around 223.4 million individuals. The usage rate of healthcare services is highest in the case of individuals suffering from PTSD. There are various symptoms that are commonly grouped into four different types: avoidance, changes in physical and emotional reactions, negative changes in thinking and mood, and intrusive memories that are identified in the individuals having post-traumatic stress disorder.

Based on the class of drug, the global post-traumatic stress disorder therapeutics market is segmented into antidepressants, anti-anxiety drugs, other drug classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants), and pipeline candidates. Rising prevalence of PTSD and the promising drug pipeline would additionally boost the post-traumatic stress disorder therapeutics market.

Geographically, the overall post-traumatic stress disorder therapeutics market is projected for the Middle East and Africa, Europe, North America, Latin America, and the Asia Pacific. North America currently drives the global market and projected to hold its supremacy throughout the forecast period. However, Europe will be clearly challenged by the Asia Pacific by the end of the forecast period. The need for post-traumatic stress disorder therapeutics drugs has become prominent in the Asia Pacific because of rapidly increasing events such as sexual assault, combats and inter-personal violence.  There are massive chances for market penetration in countries like China, and India by the market leaders who at present have a stronghold in developed countries.

The main players profiled in the study include Pfizer, Inc., GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd, Novartis AG, AstraZeneca Plc, Azevan Pharmaceuticals, Inc., Bionomics Ltd., Tonix Pharmaceuticals Holding Corp., Apotex, Inc. among others.

Access Free Sample Copy of Research Report: https://www.credenceresearch.com/sample-request/58727

[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]

Report Scope by Segments

Antidepressants

  • SSRIs
  • SNRIs
  • MAO Inhibitors
  • Tricyclic Antidepressants

Anti-anxiety Drugs

  • Beta-blockers
  • Benzodiazepines

Other Drug Class

  • Alpha-1 & Alpha-2 Receptor Antagonists
  • Atypical Antipsychotics
  • Anticonvulsants

Pipeline Candidates (Qualitative information)

  • SRX 246 (Phase II)
  • BNC 210 (Phase II)
  • Tonmya (Phase II)

By Geography Segment

  • North America (the U.S., Rest of North America)
  • Europe (U.K., Germany, France, Rest of Europe)
  • Asia Pacific (China, Japan, India, Rest of Asia Pacific)
  • Rest of the World (the Middle East & Africa, Latin America)

Key questions answered in this report

  • What are the current market trends in the post-traumatic stress disorder therapeutics market and valued opportunities for the players?
  • How the regulatory framework affects the global as well as the regional markets?
  • Which is the prominent drug class in the PTSD treatment market?
  • How does the FDA approval of products affect the global market?
  • What is the trend and market size in emerging markets such as Japan, Mexico, and Brazil?
  • Which is the largest and fastest-growing regional market?
  • Which is the largest segment by drug class in the post-traumatic stress disorder therapeutics market?
  • Which is the fastest-growing segment by drug class in the post-traumatic stress disorder therapeutics market?
  • Market assessment in terms of value.
  • Analysis of market strategies and competitive landscapes.

Access Free Sample Copy of Research Report: https://www.credenceresearch.com/sample-request/58727

Leave a Reply

Your email address will not be published. Required fields are marked *